Overview

High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma

Status:
Recruiting

Trial end date:
2024-08-01

Target enrollment:

Participant gender:

Summary

The primary objective of this single arm phase 2 trial is to assess the response rate [complete response (CR) + partial response (PR)] of combined nivolumab and HD IL-2 in subjects with metastatic melanoma and renal cell carcinoma. Response will be performed after each course of nivolumab and IL-2 using RECIST 1.1. Patients will be treated for one course past best response for a maximum of 3 courses.

Phase:

Phase 2

Details

Lead Sponsor:

Gregory Daniels
Mina Nikanjam

Treatments:

Interleukin-2
Nivolumab